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Sweet’s syndrome, also known as acute febrile neutrophilic dermatosis, is characterized predominantly
by fever, elevated neutrophil count, and erythematous skin lesions composed of plaques and nodules
that appear on upper extremities, face, or neck. The incidence of Sweet’s syndrome in the general pop-
ulation is unknown due to the rarity of the condition and potential lack of reporting. Bortezomib, an
antineoplastic agent that is the standard of care in patients with multiple myeloma, has been reported
to be associated with Sweet’s syndrome. We describe a 69-year-old man who developed Sweet’s syn-
drome during his initial course (after cycle 4) of bortezomib for treatment of multiple myeloma; he
again experienced Sweet’s syndrome 3.5 years later when rechallenged with bortezomib (after cycle 5)
for treatment of relapsed multiple myeloma. The patient’s signs, symptoms, and biopsy results were
identical during both presentations of Sweet’s syndrome. In both instances, the syndrome spontane-
ously resolved without incident and without supportive treatment with corticosteroids or antihista-
mines. To our knowledge, this is the first case report of a patient who developed Sweet’s syndrome
during an initial course of treatment with bortezomib and after rechallenge with bortezomib for
relapsed disease. As proteasome inhibitors continue to be a mainstay of therapy for both treatment and
salvage therapy for multiple myeloma, this case demonstrates that rechallenge with bortezomib is an
option for patients who develop Sweet’s syndrome.
KEY WORDS Sweet’s syndrome, bortezomib, rechallenge, drug induced, adverse reaction multiple
myeloma.
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Sweet’s syndrome, also known as acute febrile
neutrophilic dermatosis, is characterized predomi-
nantly by fever, elevated neutrophil count, and
erythematous skin lesions composed of plaques
and nodules that appear on upper extremities,
face, or neck. Histologic features include dense
mature neutrophil infiltration widely distributed
in the upper dermis.1, 2 The incidence of Sweet’s
syndrome in the general population is unknown
due to the rarity of the condition; most cases are
documented in specific case reports.3
Three types of Sweet’s syndrome have been
distinguished: classic Sweet’s syndrome, malig-
nancy-associated Sweet’s syndrome, and drug-
induced Sweet’s syndrome.1, 2 Classic Sweet’s
syndrome commonly presents in women aged
30–50 years. It may be associated with infection,
inflammatory bowel disease, or pregnancy.
Malignancy-associated Sweet’s syndrome is
temporally associated with either an initial diag-
nosis of malignancy or a leading sign of cancer
recurrence. It has been reported with all types of
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cancers; however, 85% of reported cases had
underlying hemopoietic neoplasia.1, 2 Drug-
induced Sweet’s syndrome is frequently seen in
patients treated with granulocyte colony–stimulat-
ing factor. A variety of other drugs has also been
associated with drug-induced Sweet’s syndrome
such as antibiotics, oral contraceptives, immuno-
modulating drugs, and antineoplastic agents.1, 2
Bortezomib is an antineoplastic agent that has
been reported to be associated with Sweet’s
syndrome.2, 4, 5 It is a selective proteasome
inhibitor that is highly effective for the treatment
of multiple myeloma and is a reversible inhibitor
of the 26S proteasome, which is responsible for
protein expression leading to the regulation of
cellular functions. Its role in multiple myeloma
correlates with the inhibition of nuclear factor
(NF)–j B.3
To our knowledge, there have been no pub-
lished case reports documenting the results of
rechallenging patients who experienced Sweet’s
syndrome with bortezomib; we describe a case
that occurred in a patient with relapsed multiple
myeloma.
Case Report
A 69-year-old, Caucasian man with a medical
history significant for hypertension, asthma, he-
mochromatosis, and monoclonal gammopathy
was diagnosed with smoldering (asymptomatic)
multiple myeloma. A bone marrow biopsy con-
firmed the differential diagnosis. Marrow plasma
cells represented 17% of nucleated cells, and
iron was almost absent in stores and erythro-
blasts. Hemochromatosis was treated with phle-
botomies every 3 months and darbepoetin alfa.
Myeloma progression was monitored yearly,
with no significant changes noted.
A bone marrow biopsy performed approxi-
mately 6.5 years after the initial diagnosis of
multiple myeloma revealed plasma cells repre-
senting 27% of nucleated cells, indicative of per-
sistent multiple myeloma. Iron stores were
found to be absent, similar to the previous
biopsy. Cytogenetics were performed, showing a
t(11:14) translocation, presence of p53, and 17p
deletion. At this time, the patient’s immunoglob-
ulin G (IgG)j monoclonal protein concentration
was 2.4 g/dl (> 3 g/dl at diagnosis is consistent
with multiple myleoma). He was started on sys-
temic therapy with lenalidomide and low-dose
dexamethasone.
Five months later, the patient’s IgG j mono-
clonal protein level decreased to 0.7 g/dl. The
patient was evaluated for autologous stem cell
transplantation and was determined to be a can-
didate. Antineoplastic therapy with bortezomib
was started 1 month later to prepare for trans-
plantation. The regimen consisted of an intrave-
nous bolus of bortezomib 1.3 mg/m2 on days 1,
4, 8, and 11, repeated in cycles of every 21 days.
The patient tolerated bortezomib well through
cycles 1–3, with no difficulties noted.
Two months later, after his final bortezomib
treatment during cycle 4, the patient was noted
to have developed erythematous papules over
his body and was referred to the dermatology
service.
The patient’s erythematous papules were
mostly scattered on his chest and back, whereas
his buttocks contained violaceous patches and
papules extending onto the proximal posterior
thighs. A 4-mm punch biopsy taken from the
left buttock revealed perivascular neutrophilic
inflammation and leukocytoclastic vasculitis.
The differential diagnosis revealed neutrophilic
dermatotoses, specifically Sweet’s syndrome. No
specific treatment was given, and his papules
spontaneously resolved within 10 days. Due to
the self-resolution with lack of treatment, his
case supported a mild neutrophilic drug reaction
to bortezomib.
Three and a half years after the patient’s initial
treatment with bortezomib, a similar clinical
presentation occurred after completion of cycle
5 of bortezomib. He had experienced relapse of
multiple myeloma 5 months earlier, during
which time his IgG j monoclonal protein level
steadily rose from 0.2 g/dl after autologous stem
cell transplantation to 1.2 g/dl. A subsequent
bone marrow biopsy showed plasma cells repre-
senting 21% of nucleated cells, indicating persis-
tent multiple myeloma. A decision was made to
undergo a second autologous stem cell trans-
plantation.
Bortezomib therapy was started within
1 month of the patient’s relapse of multiple mye-
loma. The patient received two cycles of an
intravenous bolus of bortezomib 1.3 mg/m2 on
days 1, 4, 8, and 11, repeated every 21 days.
After the second cycle, he started experiencing
uncomfortable tingling and numbness in his feet;
however, he continued with his treatment. The
regimen was changed to subcutaneous adminis-
tration, with the expectation of decreased neu-
ropathy. Subsequently, the patient developed
ecchymotic, erythemic areas surrounding the
injection sites, and he was switched to intrave-
nous bortezomib due to lack of improvement of
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his neuropathy. He continued with this intrave-
nous bortezomib regimen until cycle 5, at which
point he was discovered to have a slightly pru-
ritic eruption on his lower back, with numerous
spots on his upper back (Figure 1) and chest
and abdomen (Figure 2).
The dermatology service was consulted, and a
skin biopsy was conducted that revealed neutro-
philic dermatitis with perivascular lymphocytic
inflammation, similar to his previous clinical
presentation. The biopsy summary concluded
that histologic features were consistent with
Sweet’s syndrome. The dermatology service
determined that it would be safe to continue
bortezomib treatments unless the rash dissemi-
nated further.
Discussion
Bortezomib is a selective reversible proteasome
inhibitor that is highly effective for the treatment
of patients with multiple myeloma. Its main role
is to target NF–j B, a transcription factor that
promotes cell proliferation, induces antiapoptotic
cell pathways, and regulates the expression of
cell surface adhesion molecules involved with
inflammation. Bortezomib inhibits NF–j B,
hence preventing myeloma cells from binding to
bone marrow stromal cells and inhibiting angio-
genesis.4, 5 Common adverse effects reported
with bortezomib include fatigue, nausea, consti-
pation, peripheral neuropathy, peripheral edema,
thrombocytopenia, and neutropenia.6 A maculo-
papular rash was reported in 10–20% of patients
treated for multiple myeloma; however, it has
not been well characterized.6
Previous reported cases have determined that
dermatosis-related symptoms, including rash, are
not a contraindication for use.7–10 Rash is usu-
ally resolved with a combination of topical or
systemic corticosteroids and antihistamines.
High-potency topical corticosteroids, such as
0.05% clobetasol propionate, can be applied to
the lesions. Systemic corticosteroid therapy is
considered the gold standard management
approach. Dosing strategies have varied, depend-
ing on severity of symptoms, ranging from
1 mg/kg/day of prednisone to a standard dose of
30–60 mg given as a single oral morning
dose.1, 2 Treatment response to systemic corti-
costeroids is generally quick, with resolution
occurring within hours of exposure.
Prevention of rash with rechallenge is typi-
cally accomplished either by prophylactic oral
prednisone administration or concurrent intrave-
nous corticosteroids, allowing for continuation
of bortezomib therapy.7–10 If bortezomib is to be
administered subcutaneously, the package insert
states that development of local injection site
reactions can prompt reconstitution to a lower
concentration of 1 mg/ml, versus the conven-
tional concentration of 2.5 mg/ml.6
Our patient was administered a bortezomib
regimen on two separate occasions separated by
approximately 3.5 years and developed identical
symptoms and pathologic findings of Sweet’s
syndrome within a similar time frame—after
four cycles of multiple myeloma therapy. The
use of single-agent bortezomib, versus a bort-
ezomib and dexamethasone combination, high-
lights that the patient’s increase in neutrophil
count was specific to bortezomib alone. Fur-
thermore, use of the Naranjo adverse reaction
probability scale indicated a definite relation-
ship (score of 10) between the patient’s devel-
opment of Sweet’s syndrome and bortezomib
therapy (Appendix 1).
Figure 1. Erythematous papules noted on the patient’s
upper back after rechallenge with bortezomib.
Figure 2. Erythematous papules on the patient’s chest and
abdomen after rechallenge with bortezomib.
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Conclusion
To the best of our knowledge, this is the first
case report to document a patient who was suc-
cessfully rechallenged with bortezomib without
premedication with corticosteroids after previ-
ously developing Sweet’s syndrome. However,
the exclusivity of this case report lies in the
recurrence of Sweet’s syndrome after rechallenge
of bortezomib. Our patient experienced signifi-
cant neutrophilic dermatitis with perivascular
lymphocytic inflammation after two separate
instances of intravenous bortezomib administra-
tion separated by 3.5 years, with the first occur-
ring after cycle 4 and the second after cycle 5.
Proteasome inhibitors continue to be a mainstay
of therapy for both treatment and salvage ther-
apy for multiple myeloma. Thus, this case report
provides insight that rechallenge with bortezo-
mib is an option for patients who develop
Sweet’s syndrome.
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Appendix 1. The Patient’s Score Determined
by Using the Naranjo Adverse Drug Reaction
Algorithm.11
Naranjo Adverse Drug Reaction Algorithm
Question Answer Points
1. Are there previous
conclusive reports on this
reaction?
Yes +1
2. Did the adverse event
appear after the suspected
drug was given?
Yes +2
3. Did the adverse reaction
improve when the drug was
discontinued or a specific
antagonist was given?
Yes +1
4. Did the adverse reaction
appear when the drug was
re-administered?
Yes +2
5. Are there alternative
causes that could have
caused the reaction?
No +2
6. Did the reaction reappear
when a placebo was given?
Do not know
or not done
0
7. Was the drug detected in
any body fluid in toxic
concentrations?
Do not know
or not done
0
8. Was the reaction more
severe when the dose was
increased or less severe
when the dose was
decreased?
Do not know
or not done
0
9. Did the patient have a
similar reaction to the same
or similar drugs in any
previous exposure?
Yes +1
10. Was the adverse event
confirmed by any objective
evidence?
Yes +1
Total points indicating
adverse drug reaction
(ADR)
10
Naranjo Scoring key: >9 = definite ADR; 5–8 = probable ADR;
1–4 = possible ADR; 0 = doubtful ADR.
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